Healthcare provider profile · identity verified

Harry Lam, MD

Internal Medicine · LOS ANGELES, CA · NPI 1043455363

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	666	259
Amlodipine Besylate	Amlodipine Besylate	452	192
Losartan Potassium	Losartan Potassium	381	149
Gabapentin	Gabapentin	305	127
Lisinopril	Lisinopril	298	119
Rosuvastatin Calcium	Rosuvastatin Calcium	262	111
Furosemide	Furosemide	224	109
Metformin Hcl Er	Metformin Hcl	204	78
Omeprazole	Omeprazole	202	87
Levothyroxine Sodium	Levothyroxine Sodium	185	71
Glipizide	Glipizide	182	75
Atenolol	Atenolol	178	67
Hydralazine Hcl	Hydralazine Hcl	164	73
Metformin Hcl	Metformin Hcl	159	74
Albuterol Sulfate Hfa	Albuterol Sulfate	158	70
Metoprolol Tartrate	Metoprolol Tartrate	157	58
Potassium Chloride	Potassium Chloride	153	60
Pravastatin Sodium	Pravastatin Sodium	146	56
Terazosin Hcl	Terazosin Hcl	143	57
Tamsulosin Hcl	Tamsulosin Hcl	138	58
Alendronate Sodium	Alendronate Sodium	120	64
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	115	43
Trazodone Hcl	Trazodone Hcl	111	49
Jardiance	Empagliflozin	90	42
Prednisone	Prednisone	89	63
Finasteride	Finasteride	86	32
Pantoprazole Sodium	Pantoprazole Sodium	84	37
Hydrocortisone	Hydrocortisone	80	48
Clopidogrel	Clopidogrel Bisulfate	79	29
Famotidine	Famotidine	77	43
Ozempic	Semaglutide	75	11
Triamcinolone Acetonide	Triamcinolone Acetonide	74	33
Meloxicam	Meloxicam	71	33
Wixela Inhub	Fluticasone Propion/Salmeterol	70	30
Naproxen	Naproxen	66	32
Humulin N	Insulin Nph Human Isophane	64	23
Simvastatin	Simvastatin	63	29
Hydrochlorothiazide	Hydrochlorothiazide	60	30
Humulin N Kwikpen	Insulin Nph Human Isophane	59	21
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	57	22
Allopurinol	Allopurinol	53	19
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	53	18
Fenofibrate	Fenofibrate	51	17
Duloxetine Hcl	Duloxetine Hcl	50	19
Isosorbide Mononitrate Er	Isosorbide Mononitrate	49	20
Carvedilol	Carvedilol	48	23
Alprazolam	Alprazolam	46	13
Donepezil Hcl	Donepezil Hcl	45	21
Azithromycin	Azithromycin	43	39
Clobetasol Propionate	Clobetasol Propionate	43	25
Doxazosin Mesylate	Doxazosin Mesylate	43	12
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	41	41
Buspirone Hcl	Buspirone Hcl	41	17
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	41	16
Montelukast Sodium	Montelukast Sodium	41	12
Humulin R	Insulin Regular, Human	40	15
Ibuprofen	Ibuprofen	40	24
Pradaxa	Dabigatran Etexilate Mesylate	40	20
Cephalexin	Cephalexin	37	30
Eliquis	Apixaban	37	16
Spiriva Respimat	Tiotropium Bromide	36	11
Tramadol Hcl	Tramadol Hcl	36	13
Sertraline Hcl	Sertraline Hcl	35	16
Ondansetron Odt	Ondansetron	33	22
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	31	12
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	30	suppressed
Risedronate Sodium	Risedronate Sodium	30	suppressed
Ezetimibe	Ezetimibe	29	11
Acarbose	Acarbose	27	suppressed
Glipizide Er	Glipizide	27	12
Spironolactone	Spironolactone	27	12
Xarelto	Rivaroxaban	27	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	26	26
Fluticasone Propionate	Fluticasone Propionate	24	14
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	24	suppressed
Ketoconazole	Ketoconazole	24	suppressed
Metolazone	Metolazone	24	suppressed
Lidocaine-Prilocaine	Lidocaine/Prilocaine	23	suppressed
Terbinafine Hcl	Terbinafine Hcl	23	15
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	23	11
Clonidine	Clonidine	22	suppressed
Humalog Kwikpen U-100	Insulin Lispro	22	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	22	suppressed
Methadone Hcl	Methadone Hcl	22	suppressed
Nystatin	Nystatin	22	suppressed
Pregabalin	Pregabalin	22	11
Amoxicillin	Amoxicillin	21	13
Azelastine Hcl	Azelastine Hcl	21	suppressed
Levetiracetam	Levetiracetam	21	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	20	suppressed
Tradjenta	Linagliptin	20	12
Metoprolol Succinate	Metoprolol Succinate	19	suppressed
Nitroglycerin	Nitroglycerin	18	11
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	17	15
Benazepril Hcl	Benazepril Hcl	17	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	17	suppressed
Metronidazole	Metronidazole	17	11
Morphine Sulfate Er	Morphine Sulfate	17	suppressed
Estradiol	Estradiol	16	suppressed
Acyclovir	Acyclovir	15	11
Ciprofloxacin Hcl	Ciprofloxacin Hcl	15	15
Fluocinonide	Fluocinonide	15	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	15	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	15	suppressed
Lovastatin	Lovastatin	15	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	15	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	14	suppressed
Lorazepam	Lorazepam	14	suppressed
Sitagliptin	Sitagliptin	14	11
Sumatriptan Succinate	Sumatriptan Succinate	14	suppressed
Topiramate	Topiramate	14	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	14	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	14	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	14	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Lactulose	Lactulose	13	12
Ibandronate Sodium	Ibandronate Sodium	12	suppressed
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	12	suppressed
Levofloxacin	Levofloxacin	12	12
Shingrix	Varicella-Zoster Ge/As01b/Pf	12	suppressed
Tadalafil	Tadalafil	12	suppressed
Alvesco	Ciclesonide	11	suppressed
Colchicine	Colchicine	11	suppressed
Lansoprazole	Lansoprazole	11	suppressed
Mirtazapine	Mirtazapine	11	suppressed
Varenicline Tartrate	Varenicline Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error